Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002343412 | SCV002645676 | pathogenic | Cardiovascular phenotype | 2022-09-01 | criteria provided, single submitter | clinical testing | The p.W1765* pathogenic mutation (also known as c.5294G>A), located in coding exon 12 of the ALPK3 gene, results from a G to A substitution at nucleotide position 5294. This changes the amino acid from a tryptophan to a stop codon within coding exon 12. This alteration was reported as homozygous in a four-year-old subject with hypertrophic cardiomyopathy (HCM) and as heterozygous in the father who was diagnosed with HCM in adulthood (Almomani R et al. J Am Coll Cardiol, 2016 Feb;67:515-25). This alteration has also been reported as homozygous in several family members with dilated cardiomyopathy and hypertrophic cardiomyopathy phenotypes (Al Senaidi K et al. Am J Med Genet A, 2019 07;179:1235-1240). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
| OMIM | RCV000663353 | SCV000786624 | pathogenic | Cardiomyopathy, familial hypertrophic 27 | 2022-10-03 | no assertion criteria provided | literature only |